Verona Pharma Plc Stock Today
| VRNA Stock | USD 39.90 0.06 0.15% |
Performance18 of 100
| Odds Of DistressLess than 16
|
Verona Pharma is trading at 39.90 as of the 28th of November 2024, a 0.15% increase since the beginning of the trading day. The stock's open price was 39.84. Verona Pharma has less than a 16 % chance of experiencing some financial distress in the next two years of operation and had a solid performance during the last 90 days. Equity ratings for Verona Pharma PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of April 2017 | Category Healthcare | Classification Health Care |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. The company has 81.83 M outstanding shares of which 7.52 M shares are at this time shorted by private and institutional investors with about 5.78 trading days to cover. More on Verona Pharma PLC
Moving together with Verona Stock
| 0.9 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Verona Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Verona Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | David PharmD | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Jakarta Stock Exchange, Pharmaceutical Products, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVerona Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Verona Pharma's financial leverage. It provides some insight into what part of Verona Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Verona Pharma PLC (VRNA) is traded on NASDAQ Exchange in USA. It is located in 3 More London Riverside, London, United Kingdom, SE1 2RE and employs 79 people. Verona Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.26 B. Verona Pharma PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 81.83 M outstanding shares of which 7.52 M shares are at this time shorted by private and institutional investors with about 5.78 trading days to cover.
Verona Pharma PLC currently holds about 111.51 M in cash with (50.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
Check Verona Pharma Probability Of Bankruptcy
Ownership AllocationVerona Pharma PLC shows a total of 81.83 Million outstanding shares. The majority of Verona Pharma PLC outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Verona Pharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Verona Pharma PLC. Please pay attention to any change in the institutional holdings of Verona Pharma PLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Verona Ownership Details
Verona Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jennison Associates Llc | 2024-09-30 | 1.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.7 M | |
| Wellington Management Company Llp | 2024-06-30 | 1.6 M | |
| Hood River Capital Management Llc | 2024-09-30 | 1.4 M | |
| Bellevue Group Ag | 2024-09-30 | 1.2 M | |
| Citadel Advisors Llc | 2024-09-30 | 1.2 M | |
| Aisling Capital Management Lp | 2024-09-30 | 1.1 M | |
| Hhg Plc | 2024-06-30 | 1.1 M | |
| Rice Hall James & Associates, Llc | 2024-09-30 | 985.1 K | |
| Perceptive Advisors Llc | 2024-09-30 | 6.3 M | |
| Nea Management Company, Llc | 2024-06-30 | 5.6 M |
Verona Pharma Historical Income Statement
Verona Stock Against Markets
Verona Pharma Corporate Management
| Caroline Diaz | Senior Affairs | Profile | |
| LCSW BA | G Counsel | Profile | |
| Matthew Casbon | Marketing Sales | Profile | |
| Peter Spargo | Senior Controls | Profile | |
| Kathleen MD | Chief Officer | Profile | |
| B ASIA | General Counsel | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.